is an uncommon occurrence. Previously published series 1,2 reported fungi as causes of infective endocarditis in 1.3 to 6% of cases. Advances in medical and surgical therapies, including reconstructive cardiovascular surgery, implantation of intracardiac prosthetic devices, prolonged use of IV catheters, exposure to multiple broad-spectrum antibiotics, and immunosuppression, have been implicated as causes of the perceived increase in the number of cases of fungemia and FE seen during the last 2 decades. 3, 4 FE has been characterized by excessive mortality (Ͼ 50%) and morbidity, regardless of treatment. A combined medical-surgical approach seems to offer an improved outcome. However, there are no clinical trials to support or refute this opinion, largely because of the rarity of the syndrome. We reviewed clinical features, echocardiographic findings, microbiologic data, treatment, and outcome of all FE cases reported in the English-language literature between January 1, 1995, and June 30, 2000, to provide a current characterization of the syndrome.
Gore-Tex patch (W.L. Gore and Associates; Flagstaff, AZ) infections were categorized as PVE. Complicated endocarditis was defined as the presence of congestive heart failure, embolic phenomenon, valvular insufficiency, or prosthetic valve dehiscence. Relapse was defined as the return of symptoms and signs of endocarditis after an initial response to treatment that was caused by the same microorganism as was initially isolated. Long-term suppressive therapy was defined as treatment after the completion of acute treatment and administered for at least 6 months.
Statistical Analysis
Statistical analysis was performed with software (Epi Info; Centers for Disease Control and Prevention [in association with the World Health Organization]; Atlanta, GA). Categorical data were analyzed using a 2 or Fisher exact test, and the unpaired Student t test was used for continuous variables (age and follow-up). A p value Ͻ 0.05 was considered significant.
Results
To our knowledge, 152 cases of FE were reported between January 1, 1995, and June 30, 2000. 6 -96 Because of the variability in the amount of clinical data mentioned in each case, the denominator used to analyze individual demographics features was usually Ͻ 152.
Gender and Age
Gender and age were cited in 119 cases; 80 patients (67.2%) were men, and 39 patients (32.8%) were women (age range, 1 week to 84 years; mean age, 40.3 years; median age, 44 years). When patients with PVE and native valve endocarditis (NVE) were compared, there was a difference in age; the mean and median ages were 49.7 years and 53 years for patients with PVE, and 34.1 years and 33 years for patients with NVE, respectively (p Ͻ 0.001, t test).
Predisposing Factors
Predisposing factors were listed in 148 cases out of the total of 152. The most common predisposing conditions (Table 1) Note that four cases did not address the predisposing factors; therefore, 148 cases were used for calculation of percentages, rather than the total of 152 cases. †One culture-negative case with broad-spectrum antibiotics, parenteral nutrition, and underlying cardiac abnormality as predisposing conditions was included.
tients had congenital valvulopathy, 6 patients had rheumatic valvulopathy, and 1 patient had congenital and rheumatic valvulopathy. Prior IE was described in three patients, and, in one of the patients, it was associated with congenital and rheumatic valvulopathy.
Clinical and Echocardiographic Findings
Previously unrecognized or changing heart murmurs were described in 24 of 31 patients in whom there was mention of auscultatory findings at hospital admission. Echocardiograms Table 2 summarizes the types of fungi and the frequency with which they were identified. Yeasts caused 101 infections, and Candida species were recovered in 95 patients (94.1%); in 2 of the 95 cases, polymicrobial IE was caused by two different Candida species. In one other case, Candida parapsilosis was isolated with a mold, Fusarium solani. Candida albicans was the pathogen in 46 cases (45.5%).
Microbiology
Thirty-nine patients had mold infections, and in 28 patients (71.8%), Aspergillus species were recovered. Aspergillus fumigatus was most commonly identified and was recovered in 15 patients. The infecting fungus was not described in 10 patients.
The distribution of yeasts and molds causing prosthetic valve vs native valve infections was not statistically different (data not shown). Similar findings were seen for PVE differentiated into early and late categories.
Almost one half of identified pathogens (46.5%) were recovered in blood cultures; 25.2% were recovered from an intracardiac site, and 28.3% were recovered from both blood cultures and intracardiac sites. The site of microorganism isolation was not mentioned in 24 cases. Positive blood culture results were more frequent in yeast-related IE cases than in mold-related cases (81.2% vs 30.8%; p Ͻ 0.001, Mantel-Haenszel test).
Diagnosis
Clinical and microbiologic features of each case were analyzed according to the Duke criteria. IE cases were defined as either definite (n ϭ 120) or possible (n ϭ 23) in 143 patients. The IE category was not specified in the remaining nine cases, 12, 88 although the Duke criteria were used to define these cases, and they were not rejected. Among all cases classified as definite, 89.2% were based on pathologic criteria.
The interval between valve replacement and onset of infection was available in only 54 cases and ranged from 1 day to 24 years. Twenty-six cases (45.6%) and 31 cases (54.4%) were classified as early PVE and late PVE, respectively; 9 cases could not be classified because of lack of information. There was no statistical difference in the age distributions for the two groups (p ϭ 0.35, t test). Twenty-two patients had mechanical prostheses, 23 patients had biological prostheses, and in 17 patients did not have a specified prosthesis. One patient had an intra-atrial pacemaker, and three patients had cardiac patches, two of which were Gore-Tex.
Complications
Complications were reported in 100 patients (Table 3). Embolic phenomena were most commonly seen and described in 61 patients. Congestive heart failure and sepsis, the next most common complications, were seen in 16 patients each. Complications were not described in 52 patients. Seventy-four patients (48.7%) had complicated IE, with a similar distribution among yeast endocarditis and mold endocarditis cases and among NVE and PVE patients.
Therapy
Medical therapy was described in 118 cases; 111 patients (94.0%) received antifungal therapy, and no medical therapy was administered in 7 patients. Seventy-five patients (49.3%) received acute therapy, and 36 patients (23.7%) received chronic suppressive therapy after completion of acute treatment. Amphotericin B-containing compounds were used in 102 patients (91.9%) as acute therapy. Ninety-three patients were treated with conventional amphotericin B (with 5-fluocytosine or azole compounds in 26 cases); 2 patients received liposomal amphotericin B alone, and 7 patients received both conventional and lipid-associated amphotericin B. Four patients were treated with fluconazole alone, one patient received 5-fluocytosine alone, and there was no information regarding treatment for four other patients.
Long-term (Ն 6 months) suppressive therapy was administered to 13 patients after acute treatment. Eleven patients and 2 patients had FE caused by yeasts and molds, respectively. Eight patients with yeast infections were administered fluconazole; the remaining three patients received itraconazole, ketoconazole, or amphotericin B. Itraconazole was administered to the two patients with FE caused by molds (Aspergillus niger in both cases). In five other patients, suppressive therapy was administered but no specific duration of therapy was mentioned. Instead, the duration of therapy was labeled as lifelong, prolonged, or long-term.
Surgical intervention was common. Seventy-eight of 119 patients (65.5%) had surgery. No data regarding surgery were available for 33 patients. Intracardiac surgery was the most common type of surgical intervention and was performed in 63 patients. Embolectomy was performed in four patients, and both intracardiac surgery and embolectomy were performed in seven cases.
Among PVE patients, 79.6% patients underwent surgery, whereas only 53.8% of NVE patients underwent surgery (p ϭ 0.03, Mantel-Haenszel test). In addition, surgery was performed more frequently among late PVE than early PVE patients (89.6% vs ‡Includes pneumonia (n ϭ 1), disseminated intravascular coagulation and pulmonary edema (n ϭ 1), hemolytic anemia (n ϭ 1), thrombus and pneumonia (n ϭ 1), paravalvular abscess (n ϭ 1), perianular complications not specified (n ϭ 5), bradyarrhythmia (n ϭ 1), and metabolic and hematological abnormalities (n ϭ 1). There was a trend toward higher survival for patients with yeast-related endocarditis who had undergone valve surgery (68.3% of patients who underwent surgery survived, compared with 52.2% of patients who did not have surgery; p ϭ 0.20, Mantel-Haenszel test). The mortality rates for patients who received medical therapy and for patients with combined medical-surgical intervention were both approximately 50%. The mortality rates did not differ for complicated and uncomplicated FE cases, regardless of whether the patients underwent medical or combined medical and surgical therapy.
Follow-Up
Follow-up was mentioned in 36 of 53 patients who survived (range, 42 days to 17 years). Follow-up was longer for PVE cases (mean and median of 3.6 years and 1.5 years, respectively) than for NVE cases (mean and median of 1.2 years and 1 years, respectively) [p ϭ 0.03, t test]. The period of follow-up did not differ for yeast IE cases vs mold IE cases, for patients who did or did not undergo surgery, or for patients who did or did not receive lifelong suppressive therapy.
Relapse occurred in five patients (two yeastrelated and three mold-related) after a variable period ranging from 1 week to 7 months after initial response and completion of acute therapy. In one patient, two relapses caused by C albicans occurred in NVE after acute medical therapy with fluconazole was discontinued. After the second relapse and acute treatment, 17 months of suppressive therapy with fluconazole was administered; no additional relapse was noted during a 34-month follow-up. In the other four patients, one relapse was diagnosed. One patient received suppressive therapy, underwent no surgery, and relapse occurred just after suppressive therapy was stopped. In the other three patients, no suppressive therapy was administered, and relapse occurred after valve replacement.
Discussion FE is a rare illness that deserves attention. Because of a rapidly evolving epidemiology that is largely caused by advances in medical and surgical techniques, fungal infection syndromes, including FE, are relatively new complications that can threaten the success of novel therapies. In our opinion, FE should be classified as an emerging infectious disease.
FE involves a younger population. The mean age of adult patients in one review 97 was 44.3 years. In the current review, which included both children and adults, the mean and median ages were 40.3 years and 44 years, respectively.
In past years, injection drug use was considered a prominent risk factor for the development of FE. 98 In both the review by Ellis and colleagues 97 and in the current review, injection drug use was described in a minority (13% and 4.1%, respectively) of patients. In contrast, therapeutic interventions, including intravascular catheter use, valve surgery, immunosuppressive treatment, and broad-spectrum antibiotic use, were much more prevalent as risk factors for the subsequent development of FE.
Several factors positively and negatively impact our ability to diagnose FE. These factors are important because, in years past, the diagnosis was not made until postmortem examination for a sizable portion of patients. The rarity of the syndrome coupled with negative blood culture results in most mold cases and some yeast cases compromised our ability to secure an early diagnosis. However, the large vegetations that characterize this illness seem to increase the sensitivity of TTE and should prompt a consideration of FE in the setting of (blood) culture-negative endocarditis.
Establishing a definitive diagnosis of infective endocarditis is frequently a problem in which blood culture results are negative and histopathologic evidence of endocardial infection is not available. This could impact the findings of a literature review if the cases are not valid. Clinical criteria have been established to satisfy a case definition of infective endocarditis in a setting in which histopathologic evidence is not available, and these criteria have enjoyed widespread application. In the current literature review, Duke clinical criteria were infrequently needed to secure a diagnosis of FE because histopathologic evidence was obtained in 34 of 37 mold cases (91.9%) and in 67 of 77 yeast cases (87.0%). The routine availability of cardiac and/or embolic tissue for histopathologic examination and culture was, in part, due to the generally accepted doctrine that patients with proven or suspected FE undergo valve replacement in combination with medical therapy for attempted cure.
Despite a recognized dismal outcome in patients with mold endocarditis and a less-than-acceptable outcome in patients with yeast endocarditis, the choice of medical therapy has not changed in decades. Amphotericin B, as exemplified in the current literature review, remains the mainstay of medical therapy. Histopathologic and microbiologic findings of resected intracardiac tissue indicate that amphotericin B is slow to clear fungi. In one extreme example, 99 Candida species could be cultured from resected valvular tissue after 190 days of amphotericin B. Mortality caused by Aspergillus endocarditis in both recent literature reviews is Ͼ 90%, and surgical intervention with valve replacement did not improve mortality rates as compared with rates for patients who received antifungal therapy alone.
It is less clear whether the tenet that FE is a stand-alone indication for valve surgery in cases of Candida-related endocarditis is correct. Both literature surveys indicate that there may be a survival benefit to valve replacement, but they should not be overinterpreted because the data were collected retrospectively from a series of case reports. Treatment bias is inevitable in this setting because patients who are more ill are often deemed nonsurgical candidates and suffer increased mortality. Data from another investigation 100 suggested that surgical intervention did not improve outcome over that of medical therapy alone in patients with uncomplicated Candida prosthetic valve endocarditis. There are, however, potential weaknesses in the interpretation of these data. First, the number of patients in both treatment groups was small (n ϭ 10 and n ϭ 3, respectively). Second, follow-up data were not available in 5 of the 13 cases; in 3 other cases, the duration of follow-up was Յ 1 year. Thus, late relapses of FE may have been missed. Third, at least four patients received long-term antifungal suppressive therapy that could have prevented FE relapse and death. Considering all of the clinical information to date, valve replacement should probably be offered with aggressive medical therapy until prospectively collected data are generated that direct clinicians to do otherwise.
Relapsing FE is a complication seen in as many as 30 to 40% of patients who have FE develop and who survive to complete short-term therapy. 6, 9 Relapsing FE was less often seen (3.3%) in the current literature survey for at least two reasons. First, follow-up information was limited. Only 36 of the 53 patients who survived had information regarding follow-up, and for those patients listed, only 12 patients had follow-up of Ͼ 2 years. It is well recognized that relapses can occur late in FE cases and that shortterm (Ͻ 2 years) follow-up will miss episodes of late relapse. Second, the newly adopted long-term suppressive therapy 100 -102 was administered to 13 patients and likely prevented relapsing FE that would have occurred without the use of suppressive treatment.
Long-term suppressive therapy for FE is being used in two clinical scenarios. In one, the patient is deemed a nonsurgical candidate, usually for medical or surgically technical reasons, and suppressive therapy is administered after the patient's response to acute antifungal treatment. Because the patient is not considered curable without valve replacement, long-term (life-long) suppressive therapy is given. In the second scenario, long-term suppressive therapy is administered to patients who undergo valve replacement and acute treatment. Because the relapse rate is high and cure with suppressive treatment may not be achievable, 101 some cardiothoracic surgeons advocate long-term (life-long) suppressive antifungal treatment. Thus, potentially all patients who survive long enough to complete acute treatment, which can include valve replacement, may be considered candidates for chronic suppressive antifungal therapy.
FE has gained more attention in the recent literature. With our continued expansion of medical and surgical techniques, it is expected that an increasing number of these cases will occur. Advances in therapy are also needed to diminish the high mortality rate that currently characterizes FE.
